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1. Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder character‐
ized by death of pyramidal neurons in the motor cortex (upper motor neurons) and motor
neurons in the brain stem and central spinal cord (lower motor neurons). This results in
muscle weakness, progressive motor disability, and finally death by respiratory failure or
an associated infection (Shook and Pioro, 2009). There are two types of ALS familiar (fALS)
and sporadic ALS (sALS). They are both clinically undistiguishale one from the other; fALS
accounts for 10% of all cases being the rest of the cases sALS (Pasinelli and Brown, 2006).
In the last few years, there had been an explosion of genetic studies associating ALS with
several  genetic  mutations  in  genes  codifying  for  different  proteins:  Cu/Zn  superoxide
dismutase, (SOD1), transactive response binding protein 43 (TARDBP), fused in sarcoma
(FUS),  and valosin containing protein (VCP).  Most recently,  a  genetic  defect  was identi‐
fied with an expansion of the noncoding GGGGCC hexanucleotide repeat in the chromo‐
some  9,  open  reading  frame  72  (C9ORF72),  associated  with  ALS  with  and  without
frontotemporal dementia (Boeve et al., 2012).
Despite of all these discoveries the etiology of ALS remains elusive. A number of potential
pathogenic mechanisms have been associated with ALS including excitotoxicity, mitochon‐
drial dysfunction, apoptosis, glial activation, RNA-processing, growth factor abnormalities,
etc. These potential pathogenic processes are reviewed in this chapter.
2. Pathology
ALS is characterized by upper motor neuron (corticospinal motor neurons) and lower motor
neuron (bulbospinal motor neurons) degeneration and death as well as reactive gliosis
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replacing death neurons (Leigh and Garafolo, 1995). As corticospinal motor neuron degenerate
the cells suffer from a retrograde axonal loss with secondary myelin pallor and gliosis. These
changes are most severed at the brainstem and upper spinal cord, but are extended throughout
the spinal cord (Brownell et al., 1970). ALS motor cortex shows astrocytic gliosis, especially in
the deeper layers at the gray matter and underlying the subcortical white matter. Irregular
immunoreactivity to GFAP is identified in the motor strip (Kamo, et al. 1987; Ince, 2000). The
lysosomal marker CD68 also revealed that most of the glial response at the cortical and spinal
tracts corresponds to microglia activation and active macrophages (Cagnin et al., 2001; Sitte et
al., 2001). ALS affects spinal motor neurons of the ventral horn and brainstem motor neurons.
The autopsy of ALS patients shows loss of motor neurons and atrophic motor neurons with
basophilic appearance suggesting a programmed cell mechanism (Martin, 1999). The ventral
roots become thin with loss of large myelinated fibers in motor nerves leading to denervation
atrophy with evidence of reinnervation in affected muscles. Frontal temporal dementia ALS
(FTD-ALS) is a neurodegenerative disorder associated with ALS that presents typical patho‐
logical findings of the disease in addition to neuronal loss of the frontal or temporal cortex,
hippocampus and amygdale, and spongiform changes of the neocortex with (Leigh PN and
Garofolo, 1995). Non-motor findings encountered in ALS pathology are posterior columns
demyelination and reduced density of myelinated sensory fibers (Ince, 2007)
2.1. Inclusion bodies
The hallmark finding of lower motor neuron (LMN) pathology in ALS is the presence of
intracellular inclusion bodies in neuronal soma and proximal dendrites as well as glia (Barbeito
et al., 2004).
2.1.1. Ubiquitylated Inclusions (UBI)
UBI are the most common and specific inclusion in ALS, found at LMN of the spinal cord and
brainstem (Matsumoto et al., 1993) and also at the corticospinal tract upper motor neurons
(UMN) (Sasaki and Maruyama, 1994). UBI morphological spectrum goes from thread-like
ubiquitylated profiles, through skeins of different compactness to more spherical bodies (Ince
et al, 1998). The compacted lesions may be eosinophilic, basophilic and “Lewy-like” in
appearance. The composition of UBI remains unknown but several proteins were identified
in UBI such as ubiquitin (Leigh et al., 1991), peripherin (He and Hays, 2004), Cu/Zn SOD1
(Shibata 1996) and dorfin (Niwa et al., 2002). UBI are present in near 100% of sALS (Ince et al.,
2003). However, UBI are found in FTD with ubiquitin positive/tau negative inclusions. In both
fALS and sporadic types of ALS-FTD, UBI are found in cortical frontal and temporal lobe
neurons.
2.1.1.1. TAR DNA binding Protein 43 (TDP-43)
TDP-43 is a major component of ubiquinated inclusions in sALS, FTD with ubiquitin-positive
but tau-negative inclusions (non-tau FTD), FTD-ALS, and non-SOD1 fALS. TDP-43 inclusions
are practically not present in mSOD1-related fALS.
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2.1.1.2. Fused in Sarcoma protein (FUS)
Recently, mutations in the gene codifying for the fused in sarcoma protein (FUS) have been
linked to fALS. Indeed, spinal cord LMNs in fALS and sALS but not in mSOD1-fALS are
immunoreactive for FUS inclusions. These inclusions also present immunoreactivity for
TDP-43 and ubiquitin (Chaudhuri et al., 1995).
2.1.2. Bunina bodies
Bunina bodies are eosinophilic paracrystalline bodies present in the LMNs of many cases of
ALS (Piao et al., 2003). They are immunoreactive for a cysteine protease inhibitor called cystatin
C (Okamoto et al., 1993).
2.1.3. Hyaline Conglomerate Inclusions (HCI)
HCI consist of intracellular accumulation of intermediate filament proteins, especially
hyperphosphorylated neurofilament subunits and peripherin (Corbo and Hays, 2002), and are
found in the motor cortex neurons (Troost et al., 1992). HCI are much less frequently encoun‐
tered in spinal motor neurons than UBI and they are mainly associated with some types of
mSOD1 fALS. They form a larger conglomeration than UBI and are positive for silver staining,
contrary of UBI. (Ince PG and Wharton S, 2007).
3. Oxidative stress
Mutations in the gene of copper/zinc superoxide dismutase type 1 (SOD1) are the most
common cause of fALS (Rothstein, 2009; Boillee and Cleveland, 2008; Robberecht and Phillips,
2013). Recent reports indicate that SOD1 mutations may also be the cause of between 0.7 - 4%
cases of sporadic ALS (sALS) (Robberecht and Phillips, 2013). SOD1 is primarily an antioxidant
metalloenzyme that catalyzes the conversion of superoxide radical (O2.-) to oxygen (O2) and
hydrogen peroxide (H2O2). However, SOD1-linked fALS is most likely not caused by loss of
the normal SOD1 activity, but rather by a gain of a toxic function. One of the hypotheses for
mutant SOD-linked fALS toxicity proposes that an aberrant SOD1 chemistry is responsible for
the toxic gain-of-function, which allows small molecules such us peroxynitrite or hydrogen
peroxide to produce damaging free radicals. Other hypotheses for mutant SOD1 neurotoxicity
include inhibition of the proteasome activity, mitochondrial damage, and formation of
intracellular aggregates. SOD1 aggregation is an early event in ALS and could mediate motor
neuron degeneration via sequestration of cellular components, decreasing chaperone activity
and the ubiquitin proteasome pathway. Also, SOD1 mutations seem to disrupt RNA process‐
ing in the cells.
Defining the role of oxidative stress, and particularly nitrative stress in neurodegeneration has
been extremely difficult because of the multiplicity of potential targets that can be damaged
by oxidation and nitration. Certain proteins are particularly susceptible to tyrosine nitration
by the oxidant peroxynitrite (ONOO-). Tyrosine nitration is a well-established, early biomarker
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in ALS and it has been proposed that in fALS mutant SOD1 produces motor neuron death by
allowing peroxynitrite formation and catalyzing tyrosine nitration, which in turn inhibits
trophic signals (Estevez et al., 1999; Beckman et al., 1993; Crow et al., 1997; Ischiropoulos et al.,
1992; Franco and Estevez, 2011). Motor neurons are highly dependent on a continuous supply
of trophic factors to survive both in vivo and in vitro. Deprivation of trophic support in vivo by
ventral root avulsion in adult animals and axotomy in newborns, but not in adults, triggers
apoptosis (Li et al, 1994; Oppenheim, 1997; Gould and Oppenheim, 2011). Induction of
apoptosis in these conditions is preceded by induction of neuronal nitric oxide synthase
(nNOS) and nitric oxide production. Motor neuron death induced by trophic factor deprivation
requires protein synthesis and caspase activation both in vivo and in vitro (Milligan et al.,
1994; Li et al, 1998; Yaginuma et al, 2001). Cultured motor neurons deprived of trophic factors
induce nNOS expression, production of nitric oxide and peroxynitrite formation that is
followed by tyrosine nitration, which precedes motor neuron death (Estevez et al., 1998).
Inhibition of nitric oxide production and peroxynitrite formation prevents rather than delays
motor neuron death, suggesting that peroxynitrite is acting at decision-making points in the
apoptotic cascade. Deprivation of trophic factors activates the Fas pathway in motor neurons,
and inhibition of the Fas pathway prevents motor neuron death. Fas activation in motor
neurons triggers two parallel pathways: the classical extrinsic pathway recruiting FADD and
Caspase 8; and a seemingly motor neuron specific pathway, that activates DAXX/ASK1/p38
and the induction of neuronal NOS, increasing production of nitric oxide, peroxynitrite
formation and tyrosine nitration (Raoul et al, 2002).
4. Excitotoxicity
4.1. Glutamate
A dominant hypothesis of ALS pathogenesis is glutamate excitotoxicity. Glutamate is the
major excitatory neurotransmitter found in mammalian central nervous system (CNS)
however, in high concentrations is toxic to motor neurons. Some of the evidence supporting
glutamate excitotoxicity was based on the observation that exposure of neuronal cell cultures
to excess glutamate leads to cell death (Choi et al 1988). A similar observation was made in
anterior horn cells in tissue cultures of rat spinal cord where incubation with high concentra‐
tions of glutamate is associated with cell loss (Silani et al 2000). In addition, defects in glutamate
transport leading to elevated glutamate levels have been reported in mSOD1 mice and
significant number of patients with sALS (Dunlop et al., Lin et al., Rothstein et al.,). Elevated
glutamate levels were found in serum and spinal fluid of patients with sALS (Al-Chalabi, et
al 2000; Rothstein et al., 1990; Shaw, et al, 1995). Another study showed that 40% of about 400
patients with sALS have an elevation in glutamate levels that correlates with the severity of
the disease (Spreux-Varoquax et al., 2002)
The mechanism of glutamate neurotoxicity remains elusive. Excessive glutamate levels lead
to activation of glutamate ionotropic AMPA receptors in neurons and glial cells. AMPA
receptor activation triggers mitochondrial changes such as reduction in ATP synthesis,
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decreased cellular oxygen consumption, oxydative phosphorylation uncoupling, and increase
in mitochondrial reactive oxygen species (ROS) production, causing a loss in the mitochondrial
calcium buffer properties and apotosis (Heath and Shaw 2002) (Fig. 1). Rapid clearance of
glutamate at the synapsis cleft is an essential step in the prevention of motor neuron excito‐
toxicity. This step accomplished by the astrocyte glutamate transporter excitatory amino acid-2
(EAAT2) (Rothstein et,al 1996). In transgenic mice, depletion of EAAT2 has been implicated
with neuronal death (Rothstein et,al 1996). Abnormalities in EAAT2 expression were identified
in two rodent models of fALS. In the SOD1G85R transgenic mice a ~ 50% decrease in EAAT2
expression was observed in the spinal cord at the end of the disease (Bruijin et al., 1997), while
in the spinal cord ventral horn of transgenic SOD1G93A rats EAAT2 expression was decreased
before the symptomatic stage of the disease and was almost undetectable at the end of the
disease (Howland et al., 2002). Reduction in the expression of EAAT2 was found in motor
neuron disease (Fray et al 1998) and decreased glutamate transport was identified in motor
cortex and spinal cord in ALS (Rothstein et al., 1992) (Fig. 1).
4.2. Glutamate receptor
An alteration in the expression of the glutamate receptor was found in motor neurons
expressing mutant SOD1, suggesting that excitotoxicity is not only induced by increased
glutamate levels but also by alterations in the glutamate signaling pathway (Spalloni et al.,
2004). In oocytes co-expressing A4V or I113T-SOD1 with EAAT2, the mutants but not the wild
type SOD1 selectively inactivated the glial glutamate transporter in the presence of hydrogen
peroxide. This suggests that EAAT2 may be a target for mutant SOD1 toxicity (Trotti et al.,
1999). On the other hand, overexpression of EAAT2 in mutant SOD1 expressing mice delayed
the onset of motor neuron disease and decreased caspase 3 activation, the final step of the
apoptotic pathway (Guo et al 2003). In motor cortex and spinal cord extracts from ALS patients,
25% of the patients showed almost complete loss of EAAT2 protein, and 80% of the patients
showed some sort of protein abnormality (Rothstein et al., 1995) (Fig.1).
Glutamate receptor dysfunction is other possible route of excitotoxicity. Glutamate toxicity in
motor neurons is primarily mediated via alpha-amino-3-hydroxy-5-methyl-4 isoxazole
propionic acid (AMPA) receptors (Van Den Bosch et al., 2000). In patients with ALS, a
deficiency in the AMPA receptor mRNA expression was found in spinal motor neurons
(Kawahara, et al., 2004). This defect results in an increase in calcium influx through the receptor
leading to cell damaged. The increased entry in calcium in addition to the reduction in the
calcium buffer capacity due to abnormal mitochondria result in an increase in free intracellular
calcium levels, leading to motor neuron death (Bogaert et al., 2010) (Fig.1). Additionally, the
expression of the glutamate receptor subunits is reduced in ALS motor neurons (Williams et
al 1997). Another pathway leading to excitotoxicity is via deficiency in glutamate dehydro‐
genase activity (Pioro et al., 1999).
The modest protection conferred by the antigluaminergic drug riluzole in ALS patients as well
as in mutant SOD1 mice seems to support the effect of glutamate toxicity in the pathogenesis
of ALS (Lacomblez et al., 1996; Gurney et al., 1996). However, whether riluzole protects by a
mechanism related to its antiglutaminergic properties needs to be established.














Figure 1. Induction of motor neuron death by glutamate excitotoxicity. Red arrows/lines indicate the pathways
that are affected or induced in ALS.
5. Mitochondrial abnormalities
The mitochondrion is a vital organelle with multiple functions within cells. Mitochondria are
the main source of ATP, maintain calcium homeostasis and participate in calcium signaling,
and play a key role in the intrinsic apoptotic pathway. Mitochondrial malfunction turns motor
neuron more vulnerable to damage, especially in aging and stress neurons. Mitochondrial
malfunction is an important hypothesis in ALS pathogenesis (Bruijn et al., 2004; Manfredi et
al., 2005).
5.1. Mitochondrial morphology
Indeed, mitochondria morphological and ultrastructural changes as well as bioenergetic
malfunction have been reported in ALS. SOD1 is localized mainly in the cytoplasm, but has
been found also in the mitochondria and other organelles (Okado et al., 2001; Sturtz et al.,
2001). Mutant SOD1 protein is present in the mitochondrial intermembrane space, matrix and
outer membrane of mitochondria (Higgins, et al, 2002; Vijayvergiya et al., 2005; Vande Velde
et al., 2008; Kawamata et al., 2008). This abnormal SOD1 protein may fail to fold properly
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resulting in mitochondrial protein retention and mitochondrial dysfunction with damaged of
the mitochondrial membrane and loss of mitochondrial membrane potential and swelling
(Wong et al., 1995; Kong et al., 1998). Severe mitochondrial morphological changes were found
in NSC34 cells overexpressing mutant SOD1 (Raimondi et al., 2006; Menzies et al., 2002). In
addition, mitochondrial swelling and vacuolization in motor neuron axons and dendrites were
reported in mSOD1 mice even before disease onset (Wong et al., 1995; Kong et al., 1998;
Borthwick et al., 1999). The presence of abnormal mitochondrial clusters was also described
in mutant SOD1 rat motor axons (Sotelo-Silveira et al., 2009) as well as in lumbar spinal cord
motor neurons and proximal axons of sALS patients (Sasaki et al., 1996; Hirano et al., 1984).
5.2. Electron transport chain
Abnormal respiratory complex activities, disrupted redox homeostasis and decreased ATP
production were described in ALS (Borthwick et al., 1999; Jung et al., 2002; Bowling et al.,
1993; Ferri et al., 2006). Biochemical studies showed several abnormalities in mitochondrial
electron transport chain. The enzymatic activity of the electron transport chain complexes I,
II, IV was reduced in mSOD1 mice and cell cultures from patients with fALS (Jung et al.,
2002; Mattiazzi et al., 2002). The interaction between cytochrome c and the inner mitochondrial
membrane in addition to the activity of complex IV were reduced in the SOD1G93A transgenic
mice (Kirkinezos et al., 2005). Decreased oxygen consumption, lack of ADP-dependent
respiratory control, and decreased membrane potential were also reported in mutant SOD1
rat spinal astrocytes (Cassina et al., 2008) (Fig. 2).
5.3. Calcium homeostasis
Mitochondria play an important role in the intracellular calcium homeostasis as a calcium
buffer, accumulating or releasing calcium depending on the cytosolic levels. Abnormalities in
mitochondrial calcium homeostasis were reported in ALS patients and in mutant SOD1
animals (Kruman et al., 1999; Carri et al., 1997; Reiner et al, 1995; Jaiswal et al., 2009). The release
of calcium from the mitochondria leads to excessive intracellular calcium levels. This abnormal
calcium homeostasis induces motor neuron death through several mechanisms including: 1)
toxic generation of reactive oxygen species (ROS), as reported in SOD1G93A transgenic mice
(Kruman et al., 1999); 2) release of cytochrome c from the mitochondria (Martin et al., 2009);
3) glutamate excitotoxicity (Nicholls et al., 2003), and others. All these mechanisms may have
a special role in motor neurons because these cells contain less mitochondrial density per
volume compared to non-neuronal cells, thus making neurons more deficient in mitochondrial
calcium buffering properties (Grosskreutz et al., 2007) (Fig. 2). In addition, ALS patients show
a deficiency in calcium binding proteins calbidin and paralbumin in cortical motor and spinal
motor neurons. These two proteins regulate intracellular calcium levels and their deficiency
may result in neuronal loss. On the contrary, oculomotor neurons or neuron from the Onuff’s
nuclei contains normal levels of calbidin and paralbumin levels and they are preserved despite
ALS progression (Alexianu, et al. 1994; Celio, 1990; Ince et al., 1993, Palecek et al., 1999).
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 Figure 2. Mitochondrial abnormalities associated with mutant SOD1 (mSOD1). Mutant SOD1 translocates to mi‐
tochondrial intermembrane space and matrix, and is associated with the mitochondrial outer membrane. The expres‐
sion of mutant SOD1 is linked to decrease of mitochondrial membrane potential and electron transport chain activity.
The release of calcium and cytochrome c to the cytosol, and the production of ROS lead to cell death in ALS.
6. Axonal transport abnormalities
Transport of proteins, vesicles, and organelles between cell body and terminal axons is a vital
process in neuronal development, function and survival. Cytoskeletal proteins such as
neurofilament (NFs) confer structure and shape to motor neurons, and are involved in axonal
anterograde and retrograde transport between soma and motor axons. NFs are intermediate
filaments made from the assembly of light, medium, and heavy subunits (Maragakis and
Galvez-Jimenez, 2012). Disorganization of NFs affects axonal transport resulting in axonal
strangulation and accumulation of axonal cargo (Collard et al., 1995). A hallmark of ALS
pathology is the abnormal accumulation of NFs in the neuronal cell bodies and proximal axons.
Animal models and patients with ALS show that axonal transport is a critical component in
ALS pathogenesis (Morrison et al., 1998; Lin et al., 2006). Transgenic models of fALS and sALS
are associated with mutations of the heavy NF subunits (Figlewicz et al., 1994; Al-Chalabi et
al., 1999). In addition, reduction in light subunit mRNA levels was found in motor neurons
from the spinal cord of patients with ALS (Wong et al., 2000). Abnormal axonal transport,
vacuolization and degeneration of axons and motor neurons have been reported in transgenic
Current Advances in Amyotrophic Lateral Sclerosis8
mice overexpressing or with reduced expression of NF subunits (Collard et al., 1995; Cote et
al., 1993). In neurons, mitochondria are frequently found in axon terminals due to the high
demand of ATP and calcium handling at the synapses (Shepherd et al., 1998; Rowland et al.,
2000). Mitochondria are transported in both anterograde and retrograde directions via kinesin
and dynein motor complexes (Nangaku et al., 1994; Zhang, et al 2004; Varadi et al., 2004). The
disruption of the mitochondrial axonal transport has been implicated in neurodegenerative
diseases including ALS (Hollenbeck et al., 2005; De Vos et al., 2007; Magrane et al. 2009).
Mitochondria display saltatory movement along microtubules. In SOD1G93A transgenic mice
and cortical neurons transfected with G93A-SOD1, mitochondrial transport was selectively
reduced in the anterograde direction (De Vos et al., 2007). In addition, in NSC34 cells overex‐
pressing mutant SOD1 mitochondrial transport was altered in both anterograde and retro‐
grade directions (Magrane et al., 2009). Abnormalities in axonal transport cause abnormal
renewal of mitochondria and autophagosomes at distal motor axons resulting in mitochondrial
accumulation, deficit in energy production, accumulation of ROS, and released of pro-
apoptotic agents leading to neuronal death. Slow axonal transport impairment has been
described as one of the earliest pathological events in mSOD1 mice (Williamson et al., 1999;
Zhang et al. 1997). Fast axonal transport is mediated by kinesin while dynein motor complexes
mediate the transport of membrane-bound organelles necessary for axonal and synaptic
functions. In patients and transgenic rodent models of ALS there are impairments in the
kinesin-mediated anterograde transport and dynein-mediated retrograde axonal transport
(Williamson et al., 1999; Breuer et al 1987; Breuer et al., 1988; Collard et al., 1995; Sasaki et al.,
1996; Ligon et al., 2005; Parkhouse et al., 2008). Disruption of kinesin heavy chain KIF5B causes
perinuclear clustering of mitochondria in mice neurons, indicating that KIF5B is essential for
mitochondrial dispersion (Tanaka et al., 1998). Abnormalities in the transport of other proteins
such as dynactin, myosin and actine were also identified in transgenic mutant SOD1 models
(LaMonte et al., 2002). Dynactin mutations have been associated with autosomal familiar motor
neuron disease (Puls et al 2003; Puls et al 2005). Peripherin, another intermediate transport
filament was found in neuronal inclusions of sALS (Corbo et al., 1992). Overexpression of
peripherin in transgenic mice is associated with axonal degeneration. Inflammatory cytokines
increased peripherin levels, suggesting an association between inflammation and axonal
transport disorders (Sterneck, et al 1996).
7. Growth factors
Several growth factors (GFs) has been investigated and potentially implicated in the patho‐
gensis of ALS. One of the most studied GFs is the vascular endothelial growth factor (VEGF),
a protein involved in vasculogenesis and angiogenesis, and in restoration of oxygen supply
upon limited blood circulation. Animal data suggest that VEGF may be neuroprotector.
Overexpression of VEGF delayed onset and progression motor neuron disease, as shown in a
double transgenic mice generated by crossing mice expressing human mutant SOD1 with mice
overexpressing neuronal VEGF (mSOD1/VEGF). The mSOD1/VEGF transgenic mice showed
a delayed in motor neuron loss, motor impairment, and a prolonged survival compared with
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mutant SOD1 transgenic mice (Wang et al., 2007). Intracerebroventricular administration of
VEGF in a SOD1G93A rat model of ALS delayed motor neuron degeneration and onset of
paralysis, improved motor performance, preserved neuromuscular junction, and extended
survival (Storkebaum et al., 2005). This study also showed that in SOD1G93A mice, neurons
expressing a transgenic VEGF receptor prolonged mice survival. Also supporting the VEGF
neuroprotective role, a single injection of a VEGF-expressing lentiviral vector into several
muscles of SOD1G93A mice delayed the onset as well as the progression of the disease even at
onset of paralysis (Azzouz et al., 2004). Interestingly, mouse models in which the hypoxia-
response element in the VEGF gene was deleted showed a decrease in VEGF expression in
normoxia and under hypoxic conditions. This model resulted in a progressive motor neuron
degeneration disease that resembles ALS (Oosthuyse, et al., 2001). A meta-analysis of over 900
individuals from Sweden and over 1,000 individuals from Belgium and England with a specific
haplotype for VEGF associated with reduced circulating VEGF and VEGF gene transciption
showed a two-fold increase in the risk of developing ALS for these individuals (Lambrechts
et al., 2003). In another study, SOD1G93A mice crossed with VEGF haplotype mice showed a
much more severe motor neuron degeneration. VEGF probably has neuronal direct and
indirect neuroprotective effects preventing ischemic changes while regulating vascular
perfusion.
Additionally, VEGF-B, a homolog of VEGF with minimal angiogenetic activity, was shown to
be protective for cultured primary motor neurons. In addition, transgenic mice with deletion
of the VEGF-B gene were implicated in an ALS-like pathogenesis, as shown crossing a VEGF-
B knockout mouse with transgenic mice expressing human mutant SOD1 (mSOD1/VEGF-B-/-)
(Poesen et al., 2008). mSOD1/VEGF-B-/- mice showed an earlier death and more severe motor
neuron degeneration compared with mutant SOD1 transgenic mice. Intracerebroventricular
administration of VEGF-B in a SOD1G93A rat model of ALS prolonged the survival of mutant
SOD-expressing rats, suggesting that VEGF is neuroprotective by a mechanism independent
of angiogenesis (Poesen et al., 2008).
Other beneficial growth factors are innsuline growth factor-1, glial cell line –derived neuro‐
trophic factor, and brain derived neurotrophic factor.
8. RNA metabolism disorders
Ubiquinated intracytoplamsmatic inclusions containing trans-activation response DNA-
binding protein of 43 KDa (TDP-43), encoded by the TARDBP gene in chromosome-1, had
been identified in motor neurons of patients with sALS and frontal lobar degeneration (FTLD)
linked to TDP-43 pathology (FTLD-TDP) (Neumann et al., 2006). TDP-43 positive inclusions
were also identified in patients with non-SOD1 fALS. Gene mutations of the TDP-43 gene
probably accounts for 5% of patients with fALS. All the cases of sALS and SOD1 negative fALS
have neural and glial inclusions immunoreactive to both ubiquitin and TDP-43 whereas
positive SOD1 mutations in fALS were absent of TDP-43 immunoreactivity. (MacKenzie et al.,
2007; Tran et al., 2007). TDP-43 inclusions were also identified in patients with Guamanian
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parkinsonism-dementia complex, and familial British dementia (Sreedharan et al., 2008;
Kabashi et al., 2008; Van Deerlin et al., 2008; Yokoseki et al., 2008; Rutherford et al., 2008; Del
Bo et al., 2009; Hasegawa et al., 2007; Schwab et al., 2009). TDP-43 is a nuclear protein expressed
in almost all tissues that binds to mRNA and DNA and regulates mRNA processing processes
such as splicing, translation, and gene transcription. TDP-43 structure consists of two RNA
recognition motifs (RRMs) that bind to nucleic acids, and a glycine rich domain containing the
majority of ALS associated mutations (Cohen et al., 2012; Buratti et al., 2001). Genetic mutation
of another RNA processing protein, fused in sarcoma /translated in liposarcoma (FUS/TLS),
has been also associated with ALS (Kwiatkowski et al., 2009; Vance et al., 2009). The FUS/TLS
has a similar structure to TDP-43 with RRM and glycin rich domains. FUS/TLS, also a nuclear
protein, accumulates in intracytoplasmatic tau- and TDP-43 negative inclusions in patients
with fALS, sALS, and frontal lobar degeneration FTLD-FUS (Mackenzie et al., 2010). TDP-43
and FUS/TLS stabilized mRNA encoding histone deacetylase 6 (HDAC6) involved in clearance
of misfolded protein aggregates (Kim et.al, 2010, Fiesel, et al., 2010; Lee et al., 2010; Kawaguchi
et al., 2003). TDP-43 binds to a wide range of RNA targets and promotes the synthesis of several
proteins implicated in the neuronal development and integrity (Tollervey et al., 2011). TDP-43
expression is carefully controlled by a tightly autoregulated mechanism (Winton et al., 2008).
Thus, TDP-43 abnormalities in RNA binding and autoregulation, and FUS/TLS may have a
essential role in neuronal integrity. TDP-43 also has a protective effect on mitochondrial
function; abnormal expression of mitochondrial fission/fusion proteins in transgenic mice
expressing human wild-type TDP-43 transgene driven by mouse prion promoter had been
reported (Xu et al., 2010). In cultured cells, exposure to stress caused TDP-43 to be relocated
into stress granules (SGs). This abnormal localization of TDP-43 could start a pathological
TDP-43 aggregation or TDP-43 interaction with other SGs-proteins. A similar process may
occur with FUS/TLS protein (Bosco et al., 2010; Dormann et al., 2010). The formation of SGs
may lead to pathological inclusion aggregations resulting in neuronal and glial cell damage.
Hyperphosphorilated TDP-43 aggregates were identified in ALS spinal cord and FTLP-TDP
brain tissue. TDP-43 glycin-rich domain, where most of the mutations had been identified,
seems to be required for TDP-43 association with SGs. Expression of insoluble aggregates of
TDP-43 terminal fragment was implicated in the generation of SGs (Liu-Yesucevitz et al.,
2010). In addition, TDP-43 interacts with cytoplasmatic Ataxin-2 protein resulting in TDP-43
accumulation in misfolded aggregates. Mutant polyglutamine expansions within ataxin-2
enhanced the binding to TDP-43 facilitating the formation of aggregates in ALS patients
(Elden,AC et al., 2010). The formation of these aggregates seems to be implicated in neuronal
death, but the mechanism remains elusive.
9. Non-cell autonomous mechanisms
Evidence is accumulating indicating that motor neuron degeneration in ALS is not only
restricted to neuronal autonomous cell death but it is rather a more complex process involving
inflammatory neurotoxicity from non-neuronal glial cells such as astrocytes and microglia
(Phani et al., 2012). Support for non-autonomous evidence comes from several studies in
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transgenic mutant SOD1 mice. The expression of mutant SOD1 restricted to motor neurons in
vivo was not enough or caused a mild neurodegeneration (Jaarsma et. al.; 2008). Indeed, when
mutant SOD1 expression was reduced in microglia and macrophages there was a reduction
in motor neuron degeneration (Boillee 2006, Wang 2009). In addition, mutant SOD1 expression
in astrocytes is required to cause neurodegeneration by release of toxic factors (Gong et. al.,
2000; Nagai et al. 2007). Co-cultures of healthy motor neurons with astrocytes expressing
mutant SOD1 resulted in more than 50% motor neuron death (Marchetto et al, 2008), while
astrocytes obtained from postmortem tissue from patients with fALS and sALS were both toxic
to motor neurons (Haidet-Phillips et al., 2011). In agreement, mutant SOD1 knockdown in
astrocytes attenuated toxicity towards motor neurons, suggesting that the mutant enzyme
plays a role in both fALS and sALS (Phillips et al., 2011). SOD1G93A glial-restricted precursor
cells transpanted into the cervical spinal cord of wild type rats survived and differentiated
efficiently into astrocytes. These graft-derived SOD1G93A astrocytes induced host ubiquitina‐
tion and death of motor neurons, reactive astrocytosis, and reduction of the glial glutamate
transporter GLT-1 expression that was associated with animal limb weakness and respiratory
dysfunction (Papadeas et al., 2011). The SOD1G93A astrocyte-induced motor neuron death may
be madiated by host microglial activation (Papadeas et al., 2011).
Abnormalities in the immune system have also been observed in ALS patients. Blood samples
of ALS patients have increased levels of CD4+ cells and reduced levels of CD8+ T lymphocytes.
However, early in the disease when motor features are still mild there is a reduction in CD4+/
CD25+ T-regulatory cells (T-reg) and CD14+ monocytes. These observations suggest that the
reduction in circulating T-reg cells could be due to the relocation of the cells into the central
nervous system. Upon relocation, the T-reg cells would activate the innate immune cells like
microglia, leading to the release of anti-inflammatory cytokines such as interleukin-10 and
transforming growth factor-β to protect the affected area (Kipnis et al., 2004 and Mantonavi,
et al., 2009). Indeed, immunostaining for the astrocytic marker glial fibrillary acid protein
(GFAP) showed a significantly increased presence of astrocytes in the precentral gyrus of
patients with both fALS and sALS. In addition, staining for activated microglia and macro‐
phages markers such as leukocyte common antigen (LCA), lymphocytes function associate
molecule (LFA-1), complementary receptors CR3 (CD11b), and CR4 (CD11c) was also in‐
creased in motor cortex, brainstem, and corticospinal tract (Kawamata, et al., 1992; Papidimi‐
triou et al., 2010). Samples from brain and spinal cord from animal models and patient with
ALS also showed a significant increase in activated or reactive astrocytes, an indication of
neuroinflammation (Sta et al., 2011).
Astrocytes and microglia play an essential role in immune surveillance and response in the
central nervous system. Reactive astrocytes recruited to the injured area reestablish the blood-
brain-barrier (BBB), release neurotrophins and growth factors (IGF-1), clear debri, and isolate
the injured region through the formation of a glial scar (Papadimitriou et al 2010; Dong and
Benviste 2001). Microglia are also activated in the presence of antigens exposed during
neurodegeneration leading to the phagocytosis of cellular debri and the secretion of several
neurotrophic factors, neurotrophins, and cytokines. However, a poor regulation of these
factors could be harmful to motor neurons. Microglia seems to protect motor neurons from
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neurodegeneration, but is activated in the first steps of neurodegeneration. An increase in the
immunostaining for GFAP and CD11 suggests the presence of reactive astrocytes and micro‐
glia in SOD1 transgenic mice (Fischer et. al, 2004). Increase in NGF, a sign of reactive atrocytes,
leads to aptoptosis in ALS through a pathway involving activation of p75 (Pehar et al., 2004).
Additionally, in ALS animal models mutant SOD1-expressing astrocytes are neurotoxic to
motor neurons, and reducing mutant SOD1 expression decreases motor neuron degeneration
and increases animal life span (Lepore at al., 2008, Barbeito et al., 2010). The release of pro-
inflammatory cytokines, oxidative stressors such as prostanglandins, leukotrienes, and
reactive nitrogen species (RNS) is toxic to motor neurons (Henkel, et al., 2009). In in vitro
studies, normal motor neurons die through a pro-apoptotic Bax pathway when co-cultured
with astrocytes expressing mutant SOD1 (Nagai at al., 2007). In in vivo studies, microglia
releases pro-inflammatory cytokines such us TNF-α and IL-1β as well as ROS (Henkel 2009)
whereas in ALS patients, there is an increase of pro-inflammatory cytokines and prostran‐
glandin E2 (Papadimitou, 2010). Media obtained from activated microglia causes motor
neuron death by activation of TNF-α and NMDA receptors (Moisee and Strong 2006). In mouse
model of ALS, a reduction in the expression of mutant SOD1 by microglia does not change age
of symptoms onset, but slowed down disease progression (Boillee et al. 2006b). Motor neurons
expressing mutant SOD1 are more susceptible to Fas ligand and NO-triggered cell death
(Raoul et al., 2002), suggesting that in the context of ALS progression, motor neurons express‐
ing mutant SOD1 are more vulnerable to external stimuli such as ROS, RNS and toxic factors
release by surrounding cells.
10. Apoptosis
Apoptosis is a programmed cell death cascade involved in several physiological processes
during development and aging. Cell death by apoptosis sustains the homeostasis of cell
population in tissues including cell turnover, hormone dependent- and chemical induced-cell
death, and immune system development. The programmed cell death also functions as a
defense when cells are damaged by disease or noxious stimuli (Elmore, S; 2007). Thereby,
inappropriate apoptosis is a potential mechanism implicated in the pathogenesis of several
neurodegenerative disorders, including ALS (Elmore, S; 2007). There are two main apoptotic
pathways, the extrinsic or death receptor pathway and the intrinsic or mitochondrial pathway
(Igney and Krammer, 2002). The extrinsic pathway involves transmembrane receptor-
mediated interactions between ligands and death receptors resulting in transmission of death
signals from cell surface to the intracellular signaling pathways (Locksley et al., 2001). The
most studied ligand and death receptor association are Fas ligand and Fas receptor (FasL/FasR)
and tumor necrosis factor (TNF) and its receptor (TNFL/TNFR) (Hsu et al 1995; Wajant, 2002).
The intrinsic pathway consists of non-receptor-mediated stimuli that cause changes in the
inner mitochondrial membrane. These changes include the opening of mitochondrial mem‐
brane pores leading to loss of transmembrane potential and released of pro-apoptotic proteins
such as cytochrome c, Smac/DIABLO, HtrA2/Omi, and others ending with the activation of
caspases (Sealens, et al., 2004; Du et al., 2000; Van Loo et al., 2002; Garrido at al., 2005). The
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Bcl-2 family of proteins regulates the intrinsic apoptotic pathway (Cory and Adams 2002) and
these proteins in turn are regulated by the tumor suppressor protein p53 (Schuler and Green,
2001). The Bcl-2 family includes pro-apoptotic and anti-apoptotic proteins. Some of the anti-
apoptotic proteins comprise Bcl2, Bcl-x, Bcl XL, Bcl-XS, Bcl-w, BAG, whereas the pro-apoptotic
proteins include Bcl-10, BAX, Balk, Bid, Bad, Bim, Bik, and Blk. Both the intrinsic and extrinsic
pathways require a specific stimuli to activate its own caspase initiator (caspase -2,-8,-9,-10).
These two pathways, once activated, convey in the activation of a final execution pathway with
cleavage of caspase-3, resulting in DNA fragmentation, cytoskeletal and nuclear protein
cleavage, protein cross-linking, apoptotic bodies formation, expression of ligands for phago‐
cytic recognizion, and final uptake by phagocytic cells (Martinvalet, et al, 2005). There is
compelling evidence in ALS, at least in mutant SOD1-ALS, that toxicity is mediated by
apoptosis. In transgenic SOD1 mice there are numerous apoptotic findings such as DNA
fragmentation, caspase activation, and altered expression of the anti-apoptotic protein Bcl-2
(Durham HD, et al. 1997; Spooren WP et al. 2000). Motor neuron degeneration in ALS struc‐
turally resembles apoptosis. The neuronal death progression is divided in 3 sequential stages:
chromatolysis, somatodendritic attrition, and apoptosis. In ALS, in the spinal cord anterior
horn and motor cortex there is DNA fragmentation and increased in caspase-3 activity.
Vulnerable central nervous system regions affected by ALS show elevation of pro-apoptotic
proteins Bax and Bak and reduction of the antiapoptotic protein Bcl-2 in mitochondrial-
enriched membrane compartment. Co-immunoprecipitation experiments show greater Bax-
Bax interactions and lower Bax-Bcl-2 interactions in the mitochondrial-enriched membrane
compartment of ALS motor cortex compared with controls, (Martin LJ, 1999). In mutant SOD1
mice apoptotic signals are activated in sequence, caspase 1, an inflammatory caspase, is
activated at disease onset while activated caspase-3 is detected later in the curse of the disease
(Pasinelli, P, et al. 2000). In SOD1 mice, intracerebroventricular injection of a broad caspase-
inhibitor reduces caspase 1 and caspase 3 mRNA levels resulting in spear motor neurons at
the spinal cord and delay in disease onset and progression compared with vehicle-infused
mice (Li M, et al.; 2000). Overexpression of the antiapoptotic protein Bcl-2 and deletion of the
pro-apoptotic protein Bax preserve motor function and prolong life in a SOD1G93A model.
Genetic deletion of mitochondrial pro-apoptotic Bak and Bax proteins in a mouse model of
ALS prevent neuronal loss and axonal degeneration, and delayed onset of disease (Reyes et
al., 2012).
In SOD1G93A transgenic mice, cytosolic release of cytochrome c was observed (Pasinelli, et al.,
2004; Kirkinezos et al., 2005; Takeuchi et al., 2002), and levels of pro-apoptotic proteins Bad
and Bax were increased while those of anti-apoptotic proteins Bcl2, Bcl-xL and XIAP were
decreased (Guegan et al., 2001; Vukosavic et al., 1999; Ishigaki et al., 2002). Caspase 1 and
caspase 3 were also sequentially activated in motor neurons and astrocytes in SOD1G93A,
SOD1G37R, and SOD1G85R mice (Li et al., 2000; Pasinelli et al., 1998; Pasinelli et al., 2000).
Intraventricular administration of minocycline, which inhibits cytochrome c release from
mitochondria, was shown to delay disease onset and extend survival (Zhu et al., 2002).
However minocycline failed in human ALS patients (Gordon et al, 2007). Similar results were
observed upon intraventricular administration of the broad-spectrum caspase inhibitor zVAD-
fmk (Li et al., 2000). Additionally, over-expression of anti-apoptotic protein Bcl-2 delayed
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activation of the caspases, attenuated neuron degeneration and delayed disease onset and
mortality (Vukosavic et al., 1999, Kostic et al., 1997).
11. Conclusion
The research in the ALS field encounters many limitations, what is clearly reflected in the little
progress accomplished in the therapy of this neurodegenerative disorder. Most of the studies
describe the mechanisms involved in the pathogenesis of the familial form of ALS, which
accounts for a minority of all the ALS cases. However, some of the hypothesis currently under
investigation may also explain how the pathology develops in the sporadic forms of ALS. In
the last two decades several experimental models in vitro and in vivo have shaded light into
the pathogenesis of the disease. Several potential mechanisms have been implicated in ALS
onset and progression including oxidative stress, excitotoxicity, mitochondrial dysfunction,
glial activation, RNA-processing, and growth factor abnormalities. Whether these mechanisms
intertwine, work in parallel or in sequence to cause neuronal death remains to be investigated.
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